New combo aims to tame GVHD with fewer steroid side effects
NCT ID NCT05123040
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This study tested a combination of three drugs (ruxolitinib, uhCG/EGF, and steroids) to treat a severe complication called acute graft-versus-host disease (GVHD) that can occur after a stem cell transplant. The goal was to find the lowest effective steroid dose to reduce side effects while still controlling GVHD. The study included 10 participants aged 12 and older with high-risk GVHD, but it was terminated early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.